UAE-based pharmaceutical company, Julphar has signed a five-year agreement with global healthcare firm, MSD granting Julphar exclusive rights to produce, market, distribute and sell certain MSD medicines in the region. The new partnership would enhance patients’ access to cutting-edge therapies for diabetes, asthma, allergy, pain and inflammation. Both companies will seek the relevant authorities’ prior approvals on registration and production of the products locally. The licensing agreement covers UAE, Kuwait, Bahrain, Oman, Qatar and Iraq.
Wednesday, April 9- 2014 @ 1:07 UAE local time (GMT+4) Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of Mediaquest FZ LLC.